According to two anonymous sources familiar with the matter, the Trump administration is developing a framework that would permit the temporary sale of select previously restricted peptide compounds while federal health authorities work to establish new regulatory guidelines for these controversial products.
Also Read
- Japan beer giants raided over alleged price-fixing cartel
- Rahul Gandhi Detained in New Delhi as Opposition Protests Over Voter List Purge Intensify
- Democratic National Committee and Common Cause File Lawsuits Over Trump’s Use of Federal Funds for Political Ads
- Elderly Woman’s Death Ignites Nationwide Housing Protests Across Spain

